靶向治疗诱导的甲状腺癌红细胞增多症:一项回顾性研究提示的未被充分认识的安全信号
这项回顾性队列研究纳入2012至2023年两家意大利中心接受抗血管生成或靶向治疗的晚期甲状腺癌患者135例,中位随访68.5个月。红细胞增多症发生率为17.8%,RET抑制剂最高(46.7%),中位起病时间1.28个月,未检测到JAK2突变,未影响生存但疾病控制率更高。
要点
- 晚期甲状腺癌靶向治疗中红细胞增多症发生率为17.8%,RET抑制剂最高达46.7%。
- 红细胞增多症多为早期(中位1.28个月)、复发性和惰性事件,未检测到JAK2突变。
- 管理以暂时停药为主(60.0%事件),部分可减量恢复或血液科指导下放血而不停药。
核心结论
- 红细胞增多症是晚期甲状腺癌抗血管生成和靶向治疗中未被充分认识的早期、复发性和惰性不良事件,尤其见于RET抑制剂。
研究设计与样本
- 回顾性队列研究,纳入2012至2023年两家意大利中心接受抗血管生成或靶向治疗的晚期甲状腺癌患者,最终分析135例,中位随访68.5个月。
主要发现
- 24例(17.8%)发生红细胞增多症,其中16/24(66.6%)出现复发事件,总事件数50。
- 中位起病时间1.28个月(Q1-Q3:0.76-5.14)。
- RET抑制剂发生率最高(46.7%),其次为凡德他尼(20.7%)。
- 14/24例受检患者中未检测到JAK2 V617F或外显子12改变。
- 红细胞增多症与EFS、OS、ORR无关,但与更高DCR相关(p = 0.031);急性血管事件发生率在有(8.3%)与无(14.4%)红细胞增多症患者中相当。
关键数值与推荐
- 红细胞增多症依据2022年世界卫生组织标准定义,通过治疗开始后最长36个月的系列血红蛋白和血细胞比容测量评估。
- 管理方面,60.0%(30/50)的事件采取暂时中断治疗,其中53.3%(16/30)以减量恢复;部分病例(4/9,44.4%)在血液科指导下进行放血而不停药。
临床怎么用
- 对接受抗血管生成或靶向治疗(尤其RET抑制剂)的晚期甲状腺癌患者,应早期监测血红蛋白和血细胞比容以识别红细胞增多症。
- 管理可考虑暂时停药、减量恢复或血液科指导下放血,但需进一步研究优化策略。
局限性
- 回顾性研究设计,样本来自两家意大利中心,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiangiogenic and targeted therapies represent the most effective systemic options for advanced thyroid cancers. In this setting, toxicity management is essential to ensure treatment adherence. Among hematological toxicities, erythrocytosis has been rarely investigated, and its clinical pattern and management remain unclear. MATERIALS AND METHODS: We conducted a retrospective cohort study including patients with any advanced thyroid cancer histology treated with antiangiogenic or targeted therapies between 2012 and 2023 at two Italian referral centers. Therapies included RET inhibitors (RETi: selpercatinib, pralsetinib), cabozantinib, the BRAF/MEK inhibitor combination dabrafenib + trametinib, lenvatinib, sorafenib, and vandetanib. Erythrocytosis, defined according to 2022 World Health Organization criteria, was assessed through serial hemoglobin and hematocrit measurements up to 36 months from treatment start. Associations with clinical variables, event-free survival (EFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and acute vascular events were assessed using Fisher's exact and regression models, as appropriate. RESULTS: Among 173 screened patients, 135 were included in the final analysis (median follow-up 68.5 months). Erythrocytosis occurred in 24 patients (17.8%), with 16/24 (66.6%) experiencing recurrent events (total: 50). Median time to onset was 1.28 months (Q1-Q3: 0.76-5.14). RETi showed the highest incidence (46.7%), followed by vandetanib (20.7%). Among 14/24 tested patients, no JAK2 V617F or exon 12 alterations were detected. Management involved temporary treatment interruption in 60.0% (30/50) of events, with 53.3% (16/30) resuming at a reduced dose; in selected cases (4/9, 44.4%), hematology-guided phlebotomy was performed without drug discontinuation. Erythrocytosis was not associated with EFS, OS, or ORR, but was associated with higher DCR (p = 0.031). Incidence of acute vascular events was comparable among patients with (8.3%) and without (14.4%) erythrocytosis. CONCLUSIONS: Erythrocytosis represents an underrecognized, early, recurrent, and indolent adverse event of antiangiogenic and targeted therapies, particularly RETi, in advanced thyroid cancer. Its biological mechanisms and optimal management strategies warrant further investigation.
引用
- Marchesi S, Romanò R, Spagnoletti A, et al. Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study. Thyroid. 2026. PMID: 42342601. doi:10.1177/10507256261454542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。